Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency

European Journal of Pediatrics

Volumn 169, Issue 2, 2010, Pages 241-243

  Ucar, Sema Kalkan ^a   Koroğlu, Özge Altun ^a   Berk, Ömer ^a   Yalaz, Mehmet ^a   Kültürsay, Nilgün ^a   Blom, Henk J ^b   Coker, Mahmut ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5,10 methylenetetrahydrofolate reductase deficiency; Betaine; Daily dose frequency

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE; CARNITINE; FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; METHIONINE; PYRIDOXINE;

ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG EFFICACY; ENZYME DEFICIENCY; HOMOCYSTINURIA; HUMAN; LANGUAGE DEVELOPMENT; MALE; METHYLATION; METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; MOTOR DEVELOPMENT; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949424856     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-009-0997-x     Document Type: Article

References (12)

1. Abeling NG, van Gennip AH, Blom H et al (1999) Rapid diagnosis and methionine administration: basis for a favourable outcome in a patient with methylene tetrahydrofolate reductase deficiency. J Inherit Metab Dis 22:240-242.
2. Al Tawari AA, Ramadan DG, Neubauer D et al (2002) An early onset form of methylenetetrahydrofolate reductase deficiency: a report of a family from Kuwait. Brain Dev 24:304- 309.
3. Holme E, Kjellman B, Ronge E (1989) Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child 64:1061-1064.
4. Lawson-Yuen A, Levy HL (2006) The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab 88:201-207.
5. Matthews A, Johnson TN, Rostami-Hodjegan A et al (2002) An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol 54(2):140-146.
6. Mudd SH, Uhlendorf BW, Freeman JM et al (1972) Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 46:905-912.
7. Sakura N, Ono H, Nomura S et al (1998) Betaine dose and treatment intervals in therapy for homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 21:84-85.
8. Schwahn BC, Hafner D, Hohlfeld T et al (2003) Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 55(1):6-13.
9. Skiba WE, Taylor MP, Wells MS et al (1982) Human hepatic methionine biosynthesis. J Biol Chem 257:14944-14948.
10. Smith QR, Stoll JS (1998) Blood-brain barrier amino acid transport. In: Pardridge WM(ed) Introduction to the blood-brain barrier, vol. 1. Cambridge, Cambridge University Press, pp 188-197.
11. Strauss KA, Morton DH, Puffenberger EG et al (2007) Prevention of brain disease from severe 5, 10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab 91:165-175.
12. Wendel U, Bremer HI (1984) Betaine in the treatment of homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr 142:147-150.